Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZA-001 in metastatic castration resistant prostate cancer
NCT06359821Phase 1Completed
- Sponsor
- Sichuan University
- Start
- May 2024
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Modified Peptides, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZA-001 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sichuan University. Primary endpoints: Absorbed radiation doses for whole body and organ at 24 hours and Adverse Event at 1 week. Started May 2024; status: completed.
02
Drugs
ZA-001
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06359821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359821.